Minerva Neurosciences (NASDAQ:NERV) Stock Rating Upgraded by Wall Street Zen

Minerva Neurosciences (NASDAQ:NERV) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

NERV has been the subject of several other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Minerva Neurosciences in a research note on Wednesday, June 24th. Citizens Jmp began coverage on Minerva Neurosciences in a research note on Wednesday, April 15th. They set a “market outperform” rating and a $14.00 price target on the stock. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $10.50.

Minerva Neurosciences Price Performance

NERV stock opened at $4.27 on Friday. The business has a fifty day moving average price of $4.51 and a 200 day moving average price of $5.43. Minerva Neurosciences has a fifty-two week low of $1.76 and a fifty-two week high of $12.46. The stock has a market capitalization of $198.94 million, a price-to-earnings ratio of -0.15 and a beta of -0.10.

Minerva Neurosciences (NASDAQ:NERV) last released its quarterly earnings results on Friday, August 7th. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.05. On average, equities analysts expect that Minerva Neurosciences will post -0.2 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Minerva Neurosciences

A number of institutional investors and hedge funds have recently modified their holdings of the business. Seven Fleet Capital Management LP bought a new position in Minerva Neurosciences in the first quarter valued at approximately $6,855,000. DV Trading LLC acquired a new position in shares of Minerva Neurosciences in the 1st quarter valued at $5,358,000. Janus Henderson Group PLC lifted its stake in shares of Minerva Neurosciences by 47,614.0% in the 1st quarter. Janus Henderson Group PLC now owns 4,294,259 shares of the biopharmaceutical company’s stock valued at $25,873,000 after purchasing an additional 4,285,259 shares during the period. Spruce Street Capital LP bought a new position in shares of Minerva Neurosciences in the 4th quarter worth $6,655,000. Finally, Bank of America Corp DE boosted its position in shares of Minerva Neurosciences by 78,272.5% in the 1st quarter. Bank of America Corp DE now owns 39,970 shares of the biopharmaceutical company’s stock worth $241,000 after purchasing an additional 39,919 shares during the last quarter. 34.56% of the stock is owned by institutional investors.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc is a clinical?stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company’s research and development efforts are directed toward addressing unmet needs in psychiatric and neurological conditions, leveraging its expertise in neuropharmacology and receptor modulation. Minerva’s goal is to bring forward differentiated molecules that can offer improved efficacy and safety profiles compared to existing treatments.

The company’s most advanced programs include roluperidone (formerly MIN-101), which has been investigated for the treatment of negative symptoms of schizophrenia, and MIN-117, a novel serotonergic agent being evaluated in major depressive disorder.